Skip to main content
. 2021 Mar 17;2021:5548130. doi: 10.1155/2021/5548130

Figure 5.

Figure 5

The ERK pathway is inactivated in cardiomyocytes treated with bevacizumab. (a, b) Western blots were used to analyze changes in ERK phosphorylation. (c) Cell viability was measured in a CCK-8 assay. Cardiomyocytes were treated with PD98059 to inhibit ERK activity. (d) ATP production was measured using an ELISA after PD98059 treatment. p < 0.05.